Efficacy and Safety of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent
Author(s) -
Dean J. Kereiakes,
Ian T. Meredith,
Stephan Windecker,
Robert Jobe,
Shamir R. Mehta,
Ian J. Sarembock,
Robert L. Feldman,
Bernardo Stein,
Christophe Dubois,
Timothy P. Grady,
Shigeru Saito,
Takeshi Kimura,
Thomas Christen,
Dominic J. Allocco,
Keith D. Dawkins
Publication year - 2015
Publication title -
circulation cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.621
H-Index - 95
eISSN - 1941-7632
pISSN - 1941-7640
DOI - 10.1161/circinterventions.114.002372
Subject(s) - medicine , everolimus , stent , percutaneous coronary intervention , drug eluting stent , randomized controlled trial , acute coronary syndrome , surgery , thrombosis , restenosis , myocardial infarction
Drug eluting stents with durable polymers may be associated with hypersensitivity, delayed healing, and incomplete endothelialization, which may contribute to late/very late stent thrombosis and the need for prolonged dual antiplatelet therapy. Bioabsorbable polymers may facilitate stent healing, thus enhancing clinical safety. The SYNERGY stent is a thin-strut, platinum chromium metal alloy platform with an ultrathin bioabsorbable Poly(D,L-lactide-co-glycolide) abluminal everolimus-eluting polymer. We performed a multicenter, randomized controlled trial for regulatory approval to determine noninferiority of the SYNERGY stent to the durable polymer PROMUS Element Plus everolimus-eluting stent.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom